AU · rank #1 · 2026-09-10
SNT
GPW · PLN · $775M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.494 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$2.35 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $373.00 | +10.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +2.36% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | — |
| Gross margin TTM | +23.5% |
| 52w high | $398.40 |
| Market cap (USD) | $775M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik is a Polish nuclear medicine and diagnostic imaging group combining equipment distribution with radiopharmaceutical supply and recurring service contracts, generating ~441M PLN in H1 FY2025/26 revenue (+36% YoY) from continuing operations.
Rationale
The analyst_upside signal is reinforced by unanimous upward EPS revisions (100% agreement, +2.35 USD over 30/60 days) from all three covering analysts against a backdrop of genuine double-digit revenue and EBITDA growth in continuing operations, not merely sentiment rotation.
Material risks
- 1High target price dispersion (25.7%) among only three analysts means the consensus upside of 10.7% is fragile — a single estimate revision could materially shift the target, and thin coverage amplifies noise in the revision signal itself.
- 2Radioisotope supply-chain or regulatory disruption could impair the radiopharmaceutical segment, which is now the primary recurring-revenue growth engine (~334M PLN LTM, +52% YoY) and the core justification for premium valuation multiples.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.